NCT00012324已完成3 期
A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin
Eximias Pharmaceutical82 个研究点 分布在 3 个国家开始时间: 2000年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 82
- 主要终点
- Overall survival
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective for liver cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different chemotherapy regimens in treating patients who have recurrent or unresectable liver cancer.
详细描述
OBJECTIVES:
- Compare the overall survival in patients with unresectable or recurrent hepatocellular carcinoma treated with nolatrexed dihydrochloride vs doxorubicin.
- Compare time to progression, time to treatment failure, and response rates in patients treated with these regimens.
- Compare the probability of survival at 3, 6, 9, and 12 months in patients treated with these regimens.
- Compare the safety and clinical benefit of these regimens in these patients.
- Compare the response rates and survival of patients who have received prior therapy or no prior therapy after treatment with these two regimens.
- Compare the rates of conversion from unresectable to resectable lesions in patients treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to CLIP score (0-1 vs 2-3) and Karnofsky performance status (60-70% vs 80-100%). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive nolatrexed dihydrochloride IV continuously on days 1-5.
- Arm II: Patients receive doxorubicin IV on day 1. Treatment continues in both arms every 3 weeks in the absence of unacceptable toxicity or disease progression.
Patients are followed every 2 months for survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically proven or presumptive diagnosis of hepatocellular carcinoma
- •Presumptive diagnosis based on rising alpha-fetoprotein (AFP) levels over 2 assessments, CT scan or MRI of liver, spiral CT scan of portal/splenic vein, and biopsy evidence of cirrhosis
- •Unresectable or recurrent disease after prior surgical resection or embolization therapy
- •Fibrolamellar histology allowed if considered surgically unresectable based on tumor size, extrahepatic involvement, or multiple lobe involvement
- •CLIP (Cancer of the Liver Italian Program) score less than 4
- •Concurrent assignment to a transplantation list allowed
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Karnofsky 60-100%
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Absolute neutrophil count at least 1,200/mm^3
- •Platelet count at least 80,000/mm^3
- •Bilirubin no greater than 3.0 mg/dL (except for known Gilbert's Syndrome)
- •AST no greater than 5 times upper limit of normal (ULN)
- •PT no greater than 1.5 times ULN
- •Creatinine no greater than 2.0 mg/dL
- •Cardiovascular:
- •No uncontrolled hypertension within the past 3 months
- •No unstable angina, symptomatic congestive heart failure, or myocardial infarction within the past 3 months
- •No uncontrolled cardiac arrhythmia
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No active bacterial infections
- •HIV negative
- •No other primary malignancy except carcinoma in situ of the cervix or urinary bladder or non-melanoma skin cancer
- •No mental incapacitation or psychiatric illness that would preclude study participation
- •No other severe disease that would preclude study participation
- •Candidate for placement of a central venous access device
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Prior biologic therapy allowed
- •No concurrent biologic therapy
- •Chemotherapy:
- •No prior IV doxorubicin except intraarterial administration in locoregional therapy
- •Endocrine therapy:
- •Prior endocrine therapy allowed
- •No concurrent endocrine therapy
- •Radiotherapy:
- •Prior radiotherapy allowed
- •No concurrent radiotherapy
- •See Disease Characteristics
- •Surgery allowed if previously unresectable lesions become resectable
- •Recovered from any prior surgery
- •No concurrent liver transplantation
- •No other concurrent investigational or marketed anticancer drugs
- 另有 2 项未显示
排除标准
- 未提供
结局指标
主要结局
Overall survival
次要结局
- Time to treatment failure
- Survival probabilities at 3, 6, 9, and 12 months
- Safety
- Time to progression
- Response rate (complete response, partial response, stable disease)
- Response to treatment in patients with and without prior therapy
研究者
研究点 (82)
Loading locations...
相似试验
已完成
3 期
Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the EsophagusEsophageal CancerNCT00003118Alliance for Clinical Trials in Oncology56
终止
3 期
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate CancerProstate CancerNCT00024167M.D. Anderson Cancer Center265
已完成
3 期
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast CancerBreast CancerNCT00047255Jonsson Comprehensive Cancer Center263
已完成
3 期
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00003998University of Glasgow1,050
已完成
3 期
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00003636European Organisation for Research and Treatment of Cancer - EORTC704